bempedoic acid / TumCI Cancer Research Results

bemA, bempedoic acid: Click to Expand ⟱
Features:

Bempedoic acid — Bempedoic acid is a synthetic, orally administered small-molecule prodrug that is converted by very long-chain acyl-CoA synthetase 1 (ACSVL1/SLC27A2) to an active CoA thioester that inhibits ATP-citrate lyase (ACLY), thereby reducing cytosolic acetyl-CoA supply for cholesterol synthesis and de novo lipogenesis. It is formally classified as an approved lipid-lowering drug and first-in-class ACLY inhibitor; standard abbreviations include BA and BemA. Its established clinical use is cardiovascular/metabolic rather than oncologic, and its cancer relevance is currently mechanistic/preclinical, centered on tumor lipid-metabolism dependence and context-dependent immune effects. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients

Primary mechanisms (ranked):

  1. ACLY inhibition with reduced cytosolic acetyl-CoA generation, lowering sterol and fatty-acid biosynthetic flux.
  2. Suppression of de novo lipogenesis and membrane-building/anabolic support required by proliferating cancer cells.
  3. Downstream growth inhibition and apoptosis in some tumor models, including reduced invasion in selected breast and pancreatic cell systems.
  4. Immune-context modulation: ACLY inhibition can increase PUFA peroxidation, mitochondrial stress, cGAS-STING signaling, and PD-L1 expression, which may either hinder monotherapy efficacy or create combination opportunities with checkpoint blockade depending on model context.
  5. Secondary hepatocyte-linked AMPK/ACC modulation has been reported, but this is not yet the most reliable cancer-facing primary axis.

Bioavailability / PK relevance: Oral once-daily drug; FDA labeling states median Tmax is about 3.5 hours, food does not meaningfully affect oral bioavailability, plasma protein binding is very high (~99.3%), and mean half-life is about 21 hours. A key delivery constraint is biologic activation: bempedoic acid requires ACSVL1-mediated CoA conversion, with activation primarily in liver and limited activity expected in tissues lacking that enzyme, so tumor responsiveness is likely expression-context dependent rather than simply dose dependent.

In-vitro vs systemic exposure relevance: Many mechanistic oncology studies use about 25–30 µM. Reported human total Cmax is in the same broad range, but the drug is highly protein bound and antitumor activity additionally depends on cellular activation to bempedoyl-CoA, so nominal in-vitro concentrations can overstate broadly achievable free/active exposure in tumors. This is therefore not a clean “plasma concentration equals tumor effect” agent.

Clinical evidence status: Approved drug with strong cardiovascular RCT evidence, but cancer evidence remains preclinical and combination-hypothesis generating. No established oncology indication and no clear oncology trial program was identified in current major registry searches.

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ACLY and cytosolic acetyl-CoA supply ↓ ↓ (tissue-dependent) R-G Restrains anabolic carbon flow into cholesterol and fatty-acid synthesis Core validated target of the drug. Cancer relevance is strongest in tumors dependent on lipogenic flux and able to activate the prodrug.
2 De novo lipogenesis ↓ ↓ G Reduces membrane lipid supply and metabolic support for proliferation Mechanistically central downstream consequence of ACLY inhibition; likely more relevant than isolated cholesterol effects in many tumors.
3 Cell proliferation and survival ↓ proliferation; ↑ apoptosis (model-dependent) ↔ / milder effect G Growth suppression with apoptosis in selected models Supported in breast and pancreatic cell systems, especially in combination settings; not yet generalized across tumor types.
4 Invasion and metastatic behavior ↓ ↔ G Reduces invasive phenotype Observed in transwell/in vitro systems with ACLY inhibition; plausibly linked to altered lipid availability and signaling.
5 Mitochondrial damage and lipid peroxidation ↑ (context-dependent) ↔ / unclear R-G Can trigger stress signaling after ACLY blockade In immunology-focused tumor work, ACLY inhibition promoted PUFA peroxidation and mitochondrial DNA leakage rather than acting as a simple purely cytostatic metabolic block.
6 cGAS-STING innate sensing ↑ (context-dependent) ↔ R-G Activates innate stress signaling This axis may be double-edged: it can support combination immunotherapy logic, yet also induce adaptive immune escape programs.
7 PD-L1 and T-cell dysfunction axis ↑ PD-L1 Immune cells: indirect dysfunction in vivo G Potential immunosuppressive compensation Important translational caution: ACLY inhibition can blunt antitumor benefit in immunocompetent settings if used alone.
8 AMPK and ACC modulation ↑ / ↓ lipogenesis (secondary, context-dependent) ↑ in hepatocyte-dominant settings R-G Secondary metabolic reinforcement Reported in liver-focused studies and reviews, but less secure as the primary cancer-facing mechanism than direct ACLY blockade.
9 Clinical Translation Constraint Activation-limited; no oncology validation Liver-selective activation helps tolerability G Restricts direct anticancer translation Major constraints are very high protein binding, requirement for ACSVL1/SLC27A2 activation, uncertain tumor penetration/activation, hyperuricemia and tendon-rupture warnings, statin interaction constraints, and absence of oncology trials.
P: 0–30 min
R: 30 min–3 hr
G: >3 hr
TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
5510- bemA,    Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, NA
eff↑, Apoptosis↑, TumCI↓, ACLY↓, LDL↓, eff↑, TumCP↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   LDL↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Migration ⓘ

TumCI↓, 1,   TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:63  Target#:324  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page